title: Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans.
abstract: Long-lasting neuroadaptations in the glutamatergic corticostriatal circuitry have been suggested to be responsible for the persisting nature of drug addiction. In particular, animal models have linked the metabotropic glutamate receptor 5 (mGluR5) to drug-seeking behavior and extinction learning. Accordingly, blocking mGluR5s attenuated self-administration of cocaine and other addictive drugs in rats. How these animal findings extend to humans remains unclear. Therefore, we investigated if human cocaine users (CU) exhibit altered mGluR5 availability compared with drug-naïve control subjects. Seventeen male controls (11 smokers) and 18 male cocaine users (13 smokers) underwent positron emission tomography with (11)C-ABP688 to quantify mGluR5 availability in 12 volumes of interest in addiction-related brain areas. Drug use was assessed by self-report and quantitative hair toxicology. CU and controls did not significantly differ in regional mGluR5 availability. In contrast, smokers (n=24) showed significantly lower mGluR5 density throughout the brain (mean 20%) compared with non-smokers (n=11). In terms of effect sizes, lower mGluR5 availability was most pronounced in the caudate nucleus (d=1.50, 21%), insula (d=1.47, 20%), and putamen (d=1.46, 18%). Duration of smoking abstinence was positively associated with mGluR5 density in all brain regions of interest, indicating that lower mGluR5 availability was particularly pronounced in individuals who had smoked very recently. Specifically tobacco smoking was associated with lower mGluR5 availability in both CU and controls, while cocaine use was not linked to detectable mGluR5 alterations. These findings have important implications regarding the development of novel pharmacotherapies aimed at facilitating smoking cessation.
authors: Experimental and Clinical Pharmacopsychology, University Hospital of Psychiatry Zurich, Zurich, Switzerland.
authors: L M
authors: LM
authors: Hulka
authors: Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland.
authors: V
authors: V
authors: Treyer
authors: 1] Department of Psychiatry, Psychotherapy, and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland [2] Institute for Biomedical Engineering, University and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
authors: M
authors: M
authors: Scheidegger
authors: Experimental and Clinical Pharmacopsychology, University Hospital of Psychiatry Zurich, Zurich, Switzerland.
authors: K H
authors: KH
authors: Preller
authors: Experimental and Clinical Pharmacopsychology, University Hospital of Psychiatry Zurich, Zurich, Switzerland.
authors: M
authors: M
authors: Vonmoos
authors: Institute of Legal Medicine, University of Zurich, Zurich, Switzerland.
authors: M R
authors: MR
authors: Baumgartner
authors: Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, University of Zurich, Zurich, Switzerland.
authors: A
authors: A
authors: Johayem
authors: 1] Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, University of Zurich, Zurich, Switzerland [2] Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: S M
authors: SM
authors: Ametamey
authors: 1] Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland [2] Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: A
authors: A
authors: Buck
authors: 1] Department of Psychiatry, Psychotherapy, and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland [2] Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: E
authors: E
authors: Seifritz
authors: 1] Experimental and Clinical Pharmacopsychology, University Hospital of Psychiatry Zurich, Zurich, Switzerland [2] Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: B B
authors: BB
authors: Quednow
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D002421:Caudate Nucleus / Q000000981:diagnostic imaging / Q000378:metabolism; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000000981:diagnostic imaging / Q000378:metabolism*; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D010091:Oximes; D049268:Positron-Emission Tomography; D011699:Putamen / Q000000981:diagnostic imaging / Q000378:metabolism; D011725:Pyridines; D019275:Radiopharmaceuticals; D064529:Receptor, Metabotropic Glutamate 5 / Q000378:metabolism*; D057566:Self Report; D012907:Smoking / Q000378:metabolism*; D013997:Time Factors; D014029:Tobacco Use Disorder / Q000000981:diagnostic imaging / Q000378:metabolism*
chemical_list: C510950:3-(6-methylpyridin-2-ylethynyl)cyclohex-2-enone-O-methyloxime; D010091:Oximes; D011725:Pyridines; D019275:Radiopharmaceuticals; D064529:Receptor, Metabotropic Glutamate 5
references: J Nucl Med. 2006 Apr;47(4):698-705
references: 16595505
references: Synapse. 2005 Jun 15;56(4):205-16
references: 15803497
references: Eur J Neurosci. 2011 Jul;34(2):177-89
references: 21749491
references: Biol Psychiatry. 2010 Aug 1;68(3):240-8
references: 20416862
references: Biol Psychiatry. 2013 Feb 1;73(3):225-34
references: 22959126
references: Pharmacol Ther. 2006 Jul;111(1):260-71
references: 16574233
references: Drug Alcohol Depend. 2006 Jul 27;83(3):233-7
references: 16384655
references: Arch Gen Psychiatry. 1961 Jun;4:561-71
references: 13688369
references: J Neurosci. 2003 Apr 15;23(8):3531-7
references: 12716962
references: Nat Med. 2012 Apr 05;18(4):502-3
references: 22481410
references: Nucl Med Biol. 2007 Nov;34(8):1009-17
references: 17998106
references: Neuropsychopharmacology. 2006 Apr;31(4):778-86
references: 16123768
references: J Neurosci. 2007 Dec 19;27(51):13968-76
references: 18094234
references: Front Pharmacol. 2012 Aug 27;3:159
references: 22969723
references: J Pharmacol Exp Ther. 2009 Jun;329(3):1084-90
references: 19258516
references: Synapse. 1999 Mar 15;31(4):290-6
references: 10051110
references: Mol Psychiatry. 2011 Oct;16(10):974-86
references: 21519339
references: Lancet. 2012 Jan 7;379(9810):55-70
references: 22225671
references: J Cereb Blood Flow Metab. 2011 Nov;31(11):2169-80
references: 21792244
references: Biochem Biophys Res Commun. 2012 Oct 12;427(1):185-90
references: 22995293
references: Psychopharmacology (Berl). 2003 May;167(3):257-64
references: 12682710
references: J Nucl Med. 2007 Jul;48(7):1207-15
references: 17574984
references: Synapse. 2009 Jul;63(7):598-609
references: 19306440
references: Am J Med Genet A. 2004 Jan 1;124A(1):19-27
references: 14679582
references: Brain Res. 2007 Dec 12;1184:295-305
references: 17950706
references: J Nucl Med. 2007 Feb;48(2):247-52
references: 17268022
references: Alcohol Clin Exp Res. 2008 Feb;32(2):209-21
references: 18162077
references: Psychopharmacology (Berl). 2008 Feb;196(2):303-13
references: 17940751
references: Psychopharmacology (Berl). 2005 Apr;179(1):247-54
references: 15602687
references: Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):737-42
references: 23248277
references: Neuroimage. 2002 Jan;15(1):273-89
references: 11771995
references: J Neurobiol. 2002 Dec;53(4):606-17
references: 12436424
references: Neuropsychopharmacology. 2009 Mar;34(4):820-33
references: 18800068
references: J Cereb Blood Flow Metab. 2010 Aug;30(8):1538-49
references: 20531460
references: J Pharmacol Exp Ther. 2005 Mar;312(3):1232-40
references: 15550570
references: Pharmacol Biochem Behav. 2012 Feb;100(4):811-24
references: 21443897
references: Nat Rev Neurosci. 2009 Aug;10(8):561-72
references: 19571793
references: J Cereb Blood Flow Metab. 1993 Jan;13(1):24-42
references: 8380178
references: Behav Brain Res. 2009 Sep 14;202(2):238-44
references: 19463707
references: Neuropsychopharmacology. 2004 May;29(5):982-90
references: 14970829
references: Psychopharmacology (Berl). 2005 Apr;179(1):255-61
references: 15619120
references: J Neurosci. 2004 Aug 4;24(31):6939-45
references: 15295029
references: Br J Addict. 1991 Sep;86(9):1119-27
references: 1932883
references: Drug Alcohol Depend. 1993 Dec;34(1):19-28
references: 8174499
references: Neurobiol Learn Mem. 2002 Nov;78(3):637-47
references: 12559841
references: Pharmacol Biochem Behav. 2012 Feb;100(4):801-10
references: 21536062
references: Annu Rev Pharmacol Toxicol. 2012;52:321-36
references: 21961707
references: Eur J Neurol. 2012 Jan;19(1):155-62
references: 22175760
references: J Neurosci. 2001 Nov 15;21(22):9043-52
references: 11698615
references: J Biol Chem. 1992 Jul 5;267(19):13361-8
references: 1320017
references: J Biol Chem. 2003 Apr 4;278(14):12222-30
references: 12529370
references: Nat Neurosci. 2003 Jul;6(7):743-9
references: 12778052
references: Behav Res Methods. 2007 May;39(2):175-91
references: 17695343
references: Nucl Med Biol. 2010 Oct;37(7):845-51
references: 20870160
references: Am J Psychiatry. 2011 Jul;168(7):727-34
references: 21498461
references: Psychopharmacology (Berl). 2008 Oct;200(2):167-76
references: 18509621
references: Int J Neuropsychopharmacol. 2013 Apr;16(3):535-47
references: 22704223
references: Nat Neurosci. 2001 Sep;4(9):873-4
references: 11528416
references: Nat Neurosci. 2005 Nov;8(11):1481-9
references: 16251991
references: Annu Rev Neurosci. 2004;27:107-44
references: 15217328
references: Br J Psychiatry. 2013 Jul;203(1):35-43
references: 23703315
references: Neurosci Lett. 2009 Mar 13;452(2):167-71
references: 19118598
references: Biol Psychiatry. 2013 Jan 15;73(2):161-8
references: 22959709
references: Trends Pharmacol Sci. 2004 May;25(5):265-72
references: 15120493
references: J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
references: 17519979
references: Psychopharmacology (Berl). 2012 May;221(2):317-27
references: 22147259
references: Behav Pharmacol. 2007 Dec;18(8):717-24
references: 17989509